PROVIDER BULLETIN PROVIDER INFORMATION



February 1, 2022

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

Complete our medical policy feedback form online at https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center

Attn: Health Management - Medical Policy

P.O. Box 10527

Birmingham, AL 35202

Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at Policies & Guidelines (exploremyplan.com)

Policy #	Policy Title
MP-017	Wireless Capsule Endoscopy
MP-719	Surgical Treatments for Lymphedema
MP-745	Radiofrequency Coblation Tenotomy for Musculoskeletal Conditions

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at <u>Policies & Guidelines (exploremyplan.com)</u> and <u>Policies & Guidelines (exploremyplan.com)</u>

Policy #	Policy Title
PH-90277	Kanuma (sebelipase alfa)
PH-90305	Radicava (edaravone)
PH-90078	Ranibizumab: Lucentis; Byooviz
PH-90495	Feraheme (ferumoxytol)
PH-90312	Injectafer (ferric carboxymaltose injection)
PH-90524	Monoferric (ferric derisomaltose)

Bulletin P6-22

Distribution: bluecrossmn.com/providers/forms-and-publications
Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

PH-90635	Dextenza (dexamethasone insert)
PH-90634	Susvimo (ranibizumab)
PH-90633	Xipere (triamcinolone acetonide injectable suspension)